GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. - Wikidata - wikimedia - TriplyDB

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.

http://www.wikidata.org/entity/Q38028654

about

Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis ADME of biologics-what have we learned from small molecules?Revisiting the role of glycosylation in the structure of human IgG Fc.Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.Nanoengineered glycan sensors enabling native glycoprofiling for medicinal applications: towards profiling glycoproteins without labeling or liberation steps.Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.Marketing approval of mogamulizumab: a triumph for glyco-engineering.Biosimilar, biobetter and next generation therapeutic antibodies 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry.Inactivation of a GAL4-like transcription factor improves cell fitness and product yield in glycoengineered Pichia pastoris strains.One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates.Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.

P2860

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

P2860

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.

http://www.wikidata.org/entity/Q38028654

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.

@en

type

label

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.

@en

prefLabel

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.

@en

P1433

Q38028654-E38FEC2A-A9A9-437F-86D7-5B936B397042

P1476

Q38028654-4B9DABD9-EC8C-48FA-A02E-BE335316FA35

P2093

Q38028654-3FD45091-F7B5-46C7-88F2-D4710A8D2AFC

Q38028654-5376992D-9754-4420-9C85-1B64B6FFE38F

Q38028654-D713B8CA-CE9E-4136-A0ED-D6007B6FBB24

P2860

Q38028654-005A76A2-A5A6-461A-860C-6B7C02419346

Q38028654-00787BC6-3162-4ED8-9933-809F25EF59FC

Q38028654-01BDBDEB-4FA2-4850-AFF7-97106BF45B54

Q38028654-1111F454-CD6B-4ABA-818A-4B5E5548FC13

Q38028654-1369CE0D-1D70-49AD-8371-EF97420C6204

Q38028654-1977D866-B255-4BD9-83BD-CF81F22EDF64

Q38028654-23119052-BAE5-4039-81ED-9B672247306F

Q38028654-27851451-108F-47FC-982D-7D4DBC7519DE

Q38028654-29192EAA-A79D-4985-8FB3-F1C0D60712C2

Q38028654-2BE516D0-AD78-4F95-A842-FC08CE6BEE77

P304

Q38028654-8BB4BD73-7FEA-4554-95EB-8A0A22F6C878

P31

Q38028654-D1864E1A-B62C-4B31-BFB2-E67CE4A39646

P356

Q38028654-209FDD1B-84D9-44A7-894A-2CAE5F5AA600

P407

Q38028654-8FD890E7-6DCE-4449-B64D-88CB5F4FD6E1

P433

Q38028654-62ADF691-E2A9-490F-B59F-E4C6F8A6EE3E

P478

Q38028654-7A0F87AB-8F67-467E-AFE3-0D8C721DFCC5

P577

Q38028654-9590B233-C183-4B6C-9372-527FE92A70DE

P5875

Q38028654-C70322CD-AE19-4185-80A8-0641B98D3F34

P698

Q38028654-9253CBE1-59C6-4BF0-AB1B-DFE392A5FFD6

P921

Q38028654-41E75F9E-E700-4744-9B40-482B660E6569

P356

17460440903413504

P1433

Expert Opinion on Drug Discovery

P1476

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.

@en

P2093

Alain Beck

http://www.w3.org/2001/XMLSchema#string

Olivier Cochet

http://www.w3.org/2001/XMLSchema#string

Thierry Wurch

http://www.w3.org/2001/XMLSchema#string

P2860

Temperature limited fed-batch technique for control of proteolysis in Pichia pastoris bioreactor cultures

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

Moss bioreactors producing improved biopharmaceuticals

Glycosylation of therapeutic proteins in different production systems.

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells.

Cloning and disruption of the PpURA5 gene and construction of a set of integration vectors for the stable genetic modification of Pichia pastoris.

Controlled glycosylation of therapeutic antibodies in plants.

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose.

P304

95-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17460440903413504

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229551717

http://www.w3.org/2001/XMLSchema#string

P698

22823974

http://www.w3.org/2001/XMLSchema#string

P921